Reteplase

Therapeutic indications

Reteplase is indicated for:

Myocardial infarction

Population group: only adults (18 years old or older)

Reteplase is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left Bundle Branch Block within 12 hours after the onset of acute myocardial infarction AMI symptoms.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Reteplase is contraindicated in the following cases:

Haemorrhagic diathesis

Blood coagulation disorder

Oral anticoagulants

at least one of
Vitamin K antagonists
Platelet aggregation inhibitors excl. heparin
Direct thrombin inhibitors

Intracranial neoplasm, arteriovenous malformation or aneurysm

at least one of
Intracranial tumour
Intracranial vascular malformation
Cerebral aneurysm

Neoplasm with increased bleeding risk

Neoplastic disease and additionally High risk of hemorrhage

Cerebrovascular accident

at least one of
H/O: CVA
CVA - Cerebrovascular accident

External heart massage

Manual external cardiac massage with closed chest

Peptic ulceration

Peptic ulcer

Severe uncontrolled hypertension

Hypertensive crisis

Portal hypertension, oesophageal varices

at least one of
Portal hypertension
Esophageal varices

Severe renal dysfunction

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Severe liver dysfunction

Hepatic failure stage IV

Acute pancreatitis

Acute pancreatitis

Pericarditis

Pericarditis

Bacterial endocarditis

Bacterial endocarditis

Severe bleeding, major trauma, major surgery

at least one of
Bleeding
H/O: major vascular surgery
H/O: major abdominal surgery
History of major orthopedic surgery
History of cardiovascular surgery
Traumatic injury

Obstetrical delivery

Delivery procedure

Organ biopsy

Non-surgical biopsy

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: RAPILYSIN Powder and solvent for solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈